ArticleBMJ open2026
Clinical, procedural and patient-reported outcomes of the Ultimaster Nagomi sirolimus-eluting coronary stent in complex percutaneous coronary intervention: the NAGOMI COMPLEX prospective cohort study protocol.
Article in BMJ open, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT05705973 (A Post-Market Clinical Follow-up Study With Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Subjects), which is not on this map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Post-Market Clinical Follow-up Study With Ultimaster Nagomi™ Sirolimus Eluting Coronary Stent System in Complex PCI Subjects
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionPercutaneous coronary intervention (PCI) has evolved significantly over the past decade with approximately 30% of patients presenting with complex coronary artery disease, posing heightened procedural and long-term risks. Complexity in PCI is increasingly recognised as multifactorial, encompassing lesion, procedural and patient-related characteristics. The Ultimaster Nagomi sirolimus-eluting coronary stent system is designed to address the challenges of complex PCI. The NAGOMI COMPLEX study aims to assess its safety and clinical performance in a comprehensively defined complex PCI population, reflecting routine clinical practice. METHODS AND ANALYSIS: This is a prospective, multicentre, single-arm cohort study enrolling 3000 subjects undergoing complex PCI across 52 European sites. Eligible patients must meet at least one complex PCI criterion, such as multivessel PCI, bifurcation lesions, chronic total occlusions or long total stent length implantation (>60 mm). Patients will undergo PCI using the Ultimaster Nagomi sirolimus-eluting coronary stent system, with follow-up assessments conducted at 30 days, 6 months, 1 year and 2 years. The primary endpoint is Target Lesion Failure at 1 year, defined as a composite of cardiovascular death, target-vessel myocardial infarction and clinically driven target lesion revascularisation. Secondary endpoints include device success, lesion success, procedure success, rates of stent thrombosis, bleeding complications (Bleeding Academic Research Consortium (BARC 3-5)), patient-reported outcomes (EQ-5D-5L, Seattle Angina Questionnaire (SAQ-7)) and resource utilisation for health-economic analysis. Subgroup analyses will explore outcomes across clinical and procedural complexity criteria. Clinical events will be adjudicated by an independent Clinical Events Committee, while a Data Monitoring Committee will oversee safety. ETHICS AND DISSEMINATION: The study complies with the Declaration of Helsinki, EU MDR 2017/745, ISO 14155:2020, EU Regulation 2016/679 (General Data Protection Regulation), GCP and applicable national regulations. Ethics Committee approval has been obtained at all participating sites. Written informed consent is required from all subjects. Results will be disseminated through peer-reviewed publications and scientific conferences. TRIAL REGISTRATION NUMBER: NCT05705973.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.